Virtual Bioequivalence
Virtual Bioequivalence
About Virtual Bioequivalence
PharmaPure’s Virtual Bioequivalence (VBE) service offers an innovative, cost-effective alternative to traditional clinical trials. By using advanced modeling and simulations, VBE predicts the likelihood of passing bioequivalence studies before committing significant resources. This approach accelerates regulatory approval, reduces development costs, and enables faster delivery of safe, effective drugs, giving pharmaceutical companies a strategic advantage in optimizing formulations and study designs early in the process
Virtual Bioequivalence
Virtual bioequivalence (VBE) replaces the need for costly and time-consuming clinical trials. This approach expedites regulatory approval, reduces costs, and ensures faster delivery of safe, effective drugs to patients. By employing advanced modeling techniques, PharmaPure helps pharmaceutical companies achieve success with confidence and precision.
It is an innovative pre-study service designed to help clients estimate the probability of passing or failing bioequivalence (BE) studies before investing significant resources. Using advanced modeling and simulations based on preliminary data, we generate insights into the likely outcomes of BE studies. This service helps companies make informed decisions about study design, potentially reducing time, cost, and resources associated with failed studies. By leveraging virtual bioequivalence, clients gain a strategic advantage in evaluating study feasibility and optimizing formulation development early in the process.